Press Room

British Dragon Pharma is a pioneer and world leader in the development, manufacturer and marketing of controlled-release pharmaceutical products. British Dragon's shares are listed on the New York (NYSE) and Toronto Stock Exchange (TSX).

The British Dragon Press Room features the latest press releases and scientific and financial news on the company and its products, as well as a select archive of press releases and related materials.

Patent For Innovative Nanoparticle
Patent For Innovative Nanoparticle

British Dragon Pharma announced today that it has received a U.S. patent relating to its calcium phosphate nanoparticles (CAP). In addition to disclosing the compound itself, the new patent discloses methods of manufacture and use of CAP.

Read More
Transmucosal Insulin Administration
Transmucosal Insulin Administration

British Dragon Pharma announced today that it presented pre-clinical data suggesting its transmucosal insulin can deliver significant dosages of insulin into the bloodstream

Read More
Significant Testabol Propionate Phase II Efficacy Results
Significant Testabol Propionate Phase II Efficacy Results

British Dragon Pharma announced new Testabol Propionate (bioidentical testosterone propionate) Phase II clinical trial efficacy data will be presented today at the annual meeting of the American Society for Reproductive Medicine (ASRM) in Philadelphia.

Read More

Customer Reviews

Dear Friends, We are pleased to inform you that we have New Kalpa Injectable Special Offers: Testoxyl Cypionate 250, Sustaxyl 350, Trenboxyl Acetate 100. Promo time is limited.

Write a Review View Reviews

Add in Cart - Product S)

Close Button
Empty

Total Cost:

Promo Of The Month

ALL BRITISH DRAGON PRODUCTS

40% OFF

d : h : m : s
Close Button